AstraZeneca makes a quick response to FDA over Brilinta
This article was originally published in Scrip
Executive Summary
AstraZeneca has made a speedy response to the US FDA's complete response letter for its novel antiplatelet agent ticagrelor (Brilinta), but questions remain over whether the new analyses submitted will be enough to convince the US agency to approve the product.